Description

• General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
• Application: Lysophosphatidylcholine from soya bean EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
• Biochem/physiol Actions: Lysophosphatidylcholine is a major component of oxidized low density lipoproteins, and has been implicated in various inflammatory reactions, including atherosclerosis. It is used to demyelinate spinal neurons and study the processes underlying remyelination. It activates protein kinase C, p38 MAP kinase, p42 MAP Kinase, and the jun kinase (JNK) pathway, and stimulates transcription of c-jun. Lysophosphatidylcholine accumulates during cardiac ischemia and may induce arrhythmias by uncoupling gap junction communication, and increase ischemic damage by enhancing Na+ loading in cardiac myocytes. It also activates TREK1, TREK2 and TRAAK K+ channels.
• Packaging: The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
• Other Notes: Sales restrictions may apply.